Search Orphan Drug Designations and Approvals
-
Generic Name: | efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) |
---|---|
Date Designated: | 11/08/2021 |
Orphan Designation: | Treatment of Chronic Inflammatory Demyelinating Polyneuropathy |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
argenx BV Industriepark Zwijnaarde 7 Zwijnaarde, East Flanders 9052 Belgium The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-